AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of ...

AstraZeneca’s lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...

AstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The British-Swedish pharma giant on Tuesday said ...

Photo: Graeme Sloan/Bloomberg News AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients.

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast cancer compared to chemotherapy.

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

(Reuters) - London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve ...

A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.

AstraZeneca's (AZN) breast cancer therapy Truqap did not meet main goals in Phase 3 trial, but is still undergoing late-stage trials for indications. Read more here.

A decade after AstraZeneca gave up on using zibotentan to treat prostate cancer, the endothelin receptor antagonist has received a new lease on life.

AstraZeneca's breast cancer drug combination fails in late-stage trial Triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known ...